A phase I clinical trial examined the efficacy, safety, and molecular effects of the combination therapy of tesirofenib and sorafenib in patients with advanced melanoma and identified that this combination therapy resulted in dose-limiting toxicities included thrombocytopenia while the p-ERK was not inhibited [57]. Here, MAPK1 is linked to Thrombocytopenia.